Online inquiry

IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7881MR)

This product GTTS-WQ7881MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets APCS gene. The antibody can be applied in AL amyloidosis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001639.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 325
UniProt ID P02743
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7881MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6244MR IVTScrip™ mRNA-Anti-RABVgp4, CR57(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CR57
GTTS-WQ4557MR IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-936564
GTTS-WQ8572MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA Hu5F9-G4
GTTS-WQ6149MR IVTScrip™ mRNA-Anti-CTLA4, CP-675(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CP-675
GTTS-WQ5751MR IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CetuxiMab-GEX
GTTS-WQ8478MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA HTI-1088
GTTS-WQ3359MR IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AT-004
GTTS-WQ6797MR IVTScrip™ mRNA-Anti-ERBB2, DS-8201(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA DS-8201
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW